ABVC - ABVC Biopharma rises on clinical update from Phase 2 trial of ADHD drug

• ABVC Biopharma ( NASDAQ: ABVC ) said on Friday that a Phase II Part 2  study testing its ADHD drug, ABV-1505, currently being conducted at five medical centers in Taiwan, had enrolled 30 subjects and eighteen of the enrolled participants had completed the 8-week treatment.
• ( ABVC ) has risen ~5% before the bell.
• The company expects to enroll about 100 patients in Taiwan and the United States.
• The company was also notified by the University of California, San Francisco (UCSF) Medical Center Institutional Review Board that it had approved participation in the Part 2 study, set to begin in the fourth quarter of this year.
• ABVC expects to complete the Part 2 study in the third quarter of 2023.

For further details see: